Telos Corporation
NASDAQ:TLSInformation Technology Services
-$0.01 today
- Market cap
- $544.88M
- Beta
- 0.97
- P/E (TTM)
- -12.4
- EPS (TTM)
- -$0.35
Volume 0.84M
Average 0.87M
TLS Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Telos CorporationNASDAQ: TLS
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables grows, but more slowly than its trailing trend
Q1 FY2026 accounts receivables of $575K rose 34.7% year over year, behind the +58050.0% change in trailing-twelve-month accounts receivables. Sequentially, it fell 83.2% from the prior quarter. Over 3 fiscal years it compounded at -52.0% a year.
Context
- Accounts receivables amounted to 1.3% of revenue in FY2025, down 9.1 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +34.7% toward the trailing-twelve-month pace of +58050.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 2.17M USD
- Year-over-year change
- -80.7%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.17M | -80.7% |
| FY2024 | 2024-12-31 | 11.27M | +18.7% |
| FY2023 | 2023-12-31 | 9.49M | -51.8% |
| FY2022 | 2022-12-31 | 19.68M | +168.0% |
| FY2021 | 2021-12-31 | (28.94M) | — |
Accounts Receivables vs competitors
How TLS compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +58050.0% is the highest of 9, against a peer median of +0.5%.
- Accounts receivables amounts to 1.3% of revenue for TLS, versus a peer median of 2.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $276M USD | -58.1% | — | 3.7% | |
| LTM Mar 2026 | $52.34M USD | +180.6% | -34.9% | 3.0% | |
| LTM Mar 2026 | $13.69M USD | -650.8% | -33.3% | 1.7% | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥10.26M CNY | — | — | — |
| LTM Mar 2026 | $9.57M USD | -44.3% | +25.7% | 1.5% | |
| LTM Mar 2026 | $8.82M USD | +328.7% | -19.8% | 3.6% | |
| LTM Mar 2026 | $7.59M USD | +45.3% | — | 2.6% | |
| LTM Mar 2026 | $2.52M USD | -166.2% | -40.4% | 0.8% | |
| LTM Mar 2026 | $2.32M USD | +58050.0% | -52.0% | 1.3% | |
| LTM Mar 2026 | $1.89M USD | +124.3% | — | 0.9% | |
| Peer median (excluding TLS) | — | +0.5% | -33.3% | 2.1% | |
Competitors are the stored peer set for TLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (43.13M) | (53.43M) | (34.42M) | (52.52M) | (36.55M) |
| Depreciation & Amortization | 5.62M | 5.89M | 9.43M | 11.87M | 11.45M |
| Deferred Income Tax | 70K | 35K | 55K | 0 | (760K) |
| Stock-Based Compensation | 60.23M | 64.66M | 24.4M | 21.41M | 30.15M |
| Change in Working Capital | (15.57M) | (800K) | 3.33M | (18.55M) | 11.22M |
| Accounts Receivables | (28.94M) | 19.68M | 9.49M | 11.27M | 2.17M |
| Inventory | 2.05M | (1.63M) | 1.46M | (471K) | 634K |
| Accounts Payables | 16.09M | (12.32M) | (8.82M) | (9.42M) | 2.72M |
| Other Working Capital | (4.77M) | (6.52M) | 1.2M | (19.94M) | 5.69M |
| Other Non-Cash Items | 42K | 151K | (1.2M) | 11.86M | 14.67M |
| Operating Cash Flow | 7.26M | 16.51M | 1.59M | (25.94M) | 30.18M |
| Capital Expenditures | (13.17M) | (13.72M) | (15.48M) | (2.25M) | (739K) |
| Acquisitions (Net) | (5.93M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (3M) | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (9.97M) | (12.71M) | (14.55M) | (11.51M) | (8.18M) |
| Investing Cash Flow | (19.09M) | (13.72M) | (15.48M) | (16.76M) | (8.92M) |
| Debt Repayment | (1.34M) | (1.46M) | (1.59M) | (1.73M) | (1.88M) |
| Common Stock Issued | 64.27M | 0 | 0 | 203K | 108K |
| Common Stock Repurchased | (1.25M) | (11.15M) | (139K) | 0 | (13.63M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (29.33M) | 2.69M | (4.42M) | (457K) | (7.27M) |
| Financing Cash Flow | 32.35M | (9.92M) | (6.15M) | (1.98M) | (22.66M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 20.52M | (7.12M) | (20.04M) | (44.68M) | (1.4M) |
| Free Cash Flow | (5.91M) | 2.79M | (13.89M) | (28.19M) | 29.44M |
Telos Corporation
NASDAQ:TLS
Intrinsic Alpha fair value
Locked
Current Price
$7.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.